Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095105 | 0.93 | MEN1 (0.48) | DEGS1RAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL2093370 | 0.93 | DEGS1 (0.45) | DEGS1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2093208 | 0.92 | DEGS1 (0.44) | DEGS1RAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL2094420 | 0.92 | DEGS1 (0.44) | F10F2KCNH2DEGS1ALDH1A1 | |
| SCHEMBL2094049 | 0.91 | ALDH1A1 (0.48) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL2094250 | 0.91 | DEGS1 (0.45) | DEGS1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2091762 | 0.91 | DEGS1 (0.43) | F10F2KCNH2DEGS1RAB9A | |
| SCHEMBL2092699 | 0.91 | DEGS1 (0.43) | DEGS1RAB9ANPC1ALDH1A1LMNA | |
| SCHEMBL2090665 | 0.90 | MAPT (0.44) | F10F2KCNH2RAB9ANPC1 | |
| SCHEMBL2094235 | 0.90 | HDAC4 (0.44) | DEGS1RAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2004626-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-24 | — | — | EP | claimed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | claimed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | claimed |
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163777-B2 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2004626-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | NLRP3, CXCR1, CXCR2 | F10 104/4885F2 474/4885KCNH2 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.